FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to ophthalmology, and can be used in treating the patients with macular oedemas of various geneses. That is ensured by the therapy that starts with 6 sessions of plasma exchange every 2 days. It is followed by a single intravitreal introduction of antivasoproliferative preparation Avastin in dosage 1.25 mg or Lucentis in dosage 0.5 mg.
EFFECT: method allows improving clinical effectiveness combined with reduced intravitreal introduction of the antivasoproliferative preparations, due to involving pathogenetic mechanisms, namely elimination of pathological immune complexes, stabilisation of pro- and anti-inflammatory cytokines.
2 cl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TREATMENT METHOD OF AGE-RELATED MACULAR DEGENERATION | 2008 |
|
RU2368359C1 |
| METHOD FOR PREDICTING THE EFFECTIVENESS OF TREATMENT OF NEOVASCULAR FORM OF AMD | 2022 |
|
RU2788103C1 |
| SURGERY TECHNIQUE FOR SUBRETINAL HAEMORRHAGES COMBINED WITH AGE-SPECIFIC MACULAR DYSTROPHY WITH SUBRETINAL NEOVASCULAR MEMBRANE | 2008 |
|
RU2366388C1 |
| METHOD OF TREATING AGE-RELATED WET MACULAR DEGENERATION | 2013 |
|
RU2541834C1 |
| METHOD OF PREDICTING UNFAVORABLE RESPONSE TO ANTI-VEGF THERAPY FOR MACULAR NEOVASCULARIZATION BASED ON INTRAOCULAR PRESSURE INDICATORS | 2023 |
|
RU2810941C1 |
| METHOD OF COMBINED TREATMENT OF DIABETIC DIFFUSE MACULAR EDEMA | 2011 |
|
RU2486878C1 |
| METHOD OF PREDICTING AN UNFAVORABLE RESPONSE TO ANTI-VEGF THERAPY IN MACULAR NEOVASCULARIZATION BASED ON BLOOD PRESSURE PARAMETERS | 2023 |
|
RU2810940C1 |
| METHOD OF INCREASING EFFECIENCY OF PHOTODYNAMIC THERAPY OF CHOROIDAL NEOVASCULARISATION | 2008 |
|
RU2375023C1 |
| METHOD FOR TREATMENT OF MACULAR EDEMA OF RETINA | 2016 |
|
RU2635530C1 |
| METHOD FOR PREDICTION OF UNFAVORABLE RESPONSE TO ANTI-VEGF THERAPY IN MACULAR NEOVASCULARISATION BY BODY MASS INDEX | 2023 |
|
RU2821261C1 |
